Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IFSL nice volume day
nice buy/sell ratio. Maybe it even breaks 4 today?
IFSL at hod
nice volume day. Should push higher imo.
Also, should add that
if what umassoncology has stated previously is true, it doesnt even matter if drug gets approved or not. The patents alone are worth a lot imo. I think GSK would definitely be interested here imo.
this is not the way to start the week!
SP will take a hit but long term investors will see this as a buying oppty imo. Specifially only one reason cited for refusing their nda. Interesting about the 8am cc from Culley. Damage control here and the drug itself is not the problem. This can be fixed but the turnaround time to fix it and resubmit will take months. Meanwhile, we still have 514 coming up to bat. I read on one of the boards it could be ready by May and THIS is the ringer. Not 530. I will be adding more altho I wished things had turned out the other way. If nothing else we should have one helluva huge volume day today! glta longs
ESFS news out!
News must have leaked out friday:
Eco-Safe Ozone Disinfection System Sold to Longtime Chicago Meat Wholesaler
Date : 03/01/2010 @ 6:00AM
Source : MarketWire
Stock : Eco-Safe Systems USA, Inc. (ESFS)
Quote : 0.16 0.0 (0.00%) @ 2:05AM
Eco-Safe Ozone Disinfection System Sold to Longtime Chicago Meat Wholesaler
LOS ANGELES, CA -- (Marketwire) -- 03/01/10 --
Eco-Safe Systems USA, Inc. (PINKSHEETS: ESFS) is pleased to announce a sale to Nealey Foods of Chicago.
Michael Elliot, President of Eco-Safe, stated, "Nealey Foods has been in operation in Chicago for nearly 60 years, and supplies a wide variety of meats to corporate clients. We are especially pleased that this sale was motivated by the request of a nationwide restaurant chain for Nealey Foods to utilize ozone disinfection on poultry products supplied to more than 160 of their restaurants. This restaurant chain is itself currently arranging for system-wide application of Eco-Safe Ozone Systems in their restaurants."
Elliot continued, "Even though Nealey already enjoys one of the finest sanitation reputations in the industry, they saw the advantage to acquire the cutting edge technology offered by Eco-Safe, thereby assuring their nationwide restaurant chain customer of the absolute finest sanitation processing available today. When the entire supply system from wholesale processor to the customer's consumption uses ozone disinfection, the highest possible level of food safety is achieved. In addition, products are fresher when they arrive at the restaurants, and show proven increased shelf-life. Every time the product is handled, it just makes sense to disinfect with ozone, and national food chains are beginning to appreciate the benefits."
About Eco-Safe Systems:
Eco-Safe Systems, based in Los Angeles, is the manufacturer of patent pending water treatment and water reclamation systems. Our technologies produce ozonated water for food disinfection and water purification at significantly less maintenance cost and greater energy savings than our competitors in a completely green and organic manner. We currently offer supermarkets and restaurants a cost effective way to safely extend the shelf life of meat, poultry, seafood, fruits and vegetables. Please visit us at www.ecosafeusa.com for more information.
The foregoing contains forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Such forward-looking statements involve certain risks and uncertainties. The actual results may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.
Eco-Safe Contact: Michael Elliot President Eco-Safe Systems USA, Inc.
www.ecosafeusa.com Email Contact
Investor Relations & Communications: Worldwide Financial Marketing, Inc. USA Int'l: 1-954-360-9998 U.S.: 1-866-360-9998 www.wwfinancial.com
VTSI added on the dip this am
Sir Felix
thanks for that chart. I believe good managment is always the main driver on a companies performance and especially true with the pennies such as VTSI.
I didn't slap the ask
but did buy some more earlier this morning at 8 on the dip. Looks like buys moving in now with 208k vs. 157k.
I'm chewing up some green shoots already! lol
ECMH may be a gapper this am!
Morning everyone!
missy you're right about lowtrade
as far as technicals go, but you missed something. He has also stated that news trumps all! With recent events taking place sometimes you just gotta sit back and enjoy the ride! lol
not sure if you like charts or not
but he is right as far as volume etc. Profit taking was evident today but what is important is that it was done with smaller volume than the previous 2 buy days. The only surprise today to me was how the sellers moved in at the bell. Most of the time you have an early morning rise after finishing at HOD. Inexperienced maybe? No matter I will be adding tomorrow. gl
ECMH late news
pushed this one higher! weeee
weeblewobble that is so true
VTSI is now setup for making new highs. Being such a volatile stock however there will be a retracement at some point only the new low will be higher than the recent 6s. gl
that's the nice thing
about pennyland. Huge profits can be made in a short period of time. Just don't be too greedy. lol
ANX news out!
expecting some green today. This guy has served on other biotech boards such as imclone. He is a deal maker!
Companies:Adventrx Pharmaceuticals, Inc. Related Quotes
Symbol Price Change
ANX 0.32 0.00
Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Wednesday February 3, 2010, 8:00 am
SAN DIEGO, Feb. 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that Odysseas D. Kostas, M.D. will join its Board of Directors. Dr. Kostas also will serve on the Board's Audit Committee. Dr. Kostas was appointed as the representative of entities affiliated with Carl C. Icahn.
"We are delighted to welcome Odysseas to our Board of Directors," said Jack Lief, Chair of the ADVENTRX Board of Directors and the Board's Audit Committee. "His insights should prove valuable as we advance our product candidates towards commercialization."
Dr. Kostas, M.D. is an attending physician and one of seven hospitalists at Greenwich Hospital, a member of the Yale New Haven Health System and a subsidiary of Greenwich Health Care Services, Inc. At Greenwich Hospital, Dr. Kostas is a member of various committees that oversee aspects of the hospital's operational decision-making. Since March 2007, Dr. Kostas has provided advisory services to Boards of Directors of biotechnology companies, primarily in the area of strategic and partnering transactions, including ImClone Systems Incorporated prior to its sale to Eli Lilly and Company. In May 2003, Dr. Kostas founded a private medical practice that he owned and operated, treating over 2,000 patients, until May 2008. Dr. Kostas holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of Texas Southwestern Medical School and is board certified in internal medicine.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on ADVENTRX's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: successfully educating new directors and integrating new directors with existing directors and management; the risk that directors' will undertake projects that divert their respective attention from ADVENTRX matters, or that may pose a conflict of interest with ADVENTRX; ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.
ADVERTISEMENT
morning MOOvers!
Perfect storm setup here
Finished at HOD and I just got an alert from hototc.com. It is featured as a 'momentum' play. Add Clay traders chart after hours and this could easily turn into a 'hot' run tomorrow imo. glta
VTSI finished at HOD
looking for more tomorrow! :)
agree! finished at HOD
which means we move higher tomrrow am. gl
every penny stock dilutes
that is how these penny stock execs pay their bills. The problem with some of these pink and otc stocks is they they think it is an atm machine and flood the market with shares making it impossible for an investor to make any money. VTSI is one of the better stocks in that regard imo. Also, doesnt matter to me whether these people came from one board or twenty. Bottom line is we are up on heavy volume and getting noticed. Carpe diem! This may or may not continue tomorrow but I hope it does. glta
nice run today
1.8m buys vs. 375k sells. More than just a bounce imo. Yesterdays volume was high also. Time will tell. glta
VTSI could be just a bounce off
of the 6 support, but some good news and it could test its 52wk high imo
ANX nice candle
news is old but the pr today must be hitting a lot of screens imo.
ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9
Companies:Adventrx Pharmaceuticals, Inc. Related Quotes
Symbol Price Change
ANX 0.3000 +0.0205
{"s" : "anx","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Tuesday February 2, 2010, 8:00 am EST
SAN DIEGO, Feb. 2 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Principal Executive Officer, Brian M. Culley, will present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010, at 10:30 a.m. Eastern time, in the Park South room at the Waldorf Astoria in New York. Â The conference is being hosted by the Biotechnology Industry Association.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at http://www.adventrx.com/. Â An archived presentation will be available on the Web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. Â More information can be found on the Company's Web site at http://www.adventrx.com/. Â
VTSI pumping some iron
4th qtr is coming :)
GCMN 8k filed
yes!
GCMN 8k filed
- Current report filing (8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 27, 2010
GOLD CREST MINES, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-52392
82-0290112
(State or other jurisdiction of incorporation or organization)
Commission file number
(IRS Employer Identification Number)
724 E. Metler Lane
Spokane, WA
99218
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (509) 893-0171
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On January 27, 2010, the Company, through its wholly owned subsidiaries, Kisa Gold Mining, Inc. and Golden Lynx, LLC signed an option agreement with North Fork Resources Pty Ltd (“North Fork”) which grants North Fork an exclusive option to purchase and/or earn an interest in the Company’s Southwest Kuskokwim Project area. The Southwest Kuskokwim Project area consists of exploration properties in southwest Alaska approximately 90 miles east of the village of Bethel covering approximately 35,240 acres of State of Alaska-owned lands in 7 claim groups known as the Kisa, Luna, AKO, GL, Little Swift, Gold Creek and Gossan Valley within the Kuskokwim Mineral Belt.
Under the terms of the option, North Fork will make a payment to the Company in the amount of $20,000 within 14 days of the signing of the agreement which was January 27, 2010 for the exclusive right to explore the claims up until October 31, 2010. During the option period, North Fork agrees to meet the minimum annual expenditure requirements on the claims for the period up to September 1, 2010. Following the expiration of the option on October 31, 2010, North Fork will have 30 days to notify the Company of its decision to exercise its option to purchase and/or earn into any or all of the claim groups.
The following is a breakdown of the proposed earn-in terms:
1.
The initial interest at the time North Fork exercises its option to earn into the Projects will be as follows:
a.
Gold Crest Mines, Inc. – 100%
b.
North Fork – 0%
2.
North Fork can earn a 51% interest in the Projects by the expenditure of $3,000,000USD on the Projects by October 31, 2013.
3.
If North Fork withdraws from the Joint Venture prior to earning a 51% interest in the Projects, it will have no further interest in the Projects.
4.
North Fork can earn an additional 24% interest in the Projects, taking its total interest to 75% by the expenditure of an additional $3,000,000USD by October 31, 2016.
5.
North Fork can earn a total interest of 90% in any of the Project claim blocks by the completion of a Bankable Feasibility Study (BFS).
6.
Gold Crest Mines, Inc. will retain a free carried 10% interest in the Projects up to a Decision to Mine at which point it can elect to contribute at 10% or dilute to a 2% Net Smelter Royalty.
7.
North Fork is obliged to keep the Projects in “good standing”.
8.
North Fork is the sole manager of the Projects and will make all decisions in regards to the exploration programs.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
GOLD CREST MINES, INC.
By:
/s/ Matt J. Colbert
Matt J. Colbert
Chief Financial Officer
Date: January 29, 2010
VTSI moving up
from 6 bottom on no news.
morning MOOvers!
ECMH ut :)
ECMH rollin!
ECMH another filing
uplisting coming soon?
http://ih.advfn.com/p.php?pid=nmona&cb=1264797017&article=41320274&symbol=NO%5EECMH
there will be a big push up
once these shorts have to cover imo. Feb. 9th is drawing closer and with its approach more buying speculation will put upward pressure on the sp imo. I see a good trade here for someone buying at this price imo. gl
gone most of the day
looks like some shares were released last week which precipitated the big selloff imo.
CCTC on watch
should bounce once dumpage is done.
chartwise all red last few days.
it is a possibility
I have another drug co. INSV which has a partnership with Bausch & Lomb and they receive royalties from that. Could be a JV partnership or licensing deal. This technology can be applied to other cancer drugs having problems with onsite reactions which would add to the bottom line also imo.
For third party and medicare reimbursement
ANX may need prior approval since it is not now presently the drug of choice to use. However, once it is proven to do what it says it can it will move up the ladder of doctors choices imo. There are other expensive drugs that are covered with PA so not a big deal for ANX imo. The other generics stll pose the same risky injection site reactions as the brand btw so doctors will probably shun those in favor of ANX imo. Other generics won't capture much of the market share imo. Don't let AF and his shorty gang fool you into selling here. They will be crushed in due time imo. gl
Some notes on ANX
on the recent sp decline. Longs have been taking a beating here last few days but should realize that the fundamentals haven't changed here imo. It seems after the conference was over the daytraders pulled their profits and moved elsewhere since the buyout rumors were false and the 'buzz' died down. Adam F. and his group of shorties added to the drop with his truth twisting of the facts. Firstly, Brian C. never said that the US sales were 200m but 200m worldwide. Also, this quote from his blog really galls me:
"Vinorelbine is very cheap and vein irritation occurs in only about 30% of patients, so it's not a huge problem. ANX-530 is simply not differentiated enough for doctors to switch, especially since ANX-530 will cost more"
I'm sorry but 30% is a huge number for a reaction like that. Lots people freak out when the number is only 5 or 10%. I believe that is the main reason why doctors haven't used the drug more in the past and with ANX 530 sales should dramatically increase imo.
Lastly, I would like to point out the fact that if ANX does get bought out the reason won't necessarily be for its 2 new drugs but more for the new technology it has brought to the marketplace. I say this because a few years ago I was involed with another drug company (forget the old name) but it had a time release formula that worked for CII drugs. It was bought out by Alza I believe. They were much like ANX in that they only had a couple of drugs but their technology improved what was in the marketplace at the time. Some investors scored big there and I see the same thing happening here for those willing to hold long. The smart money here is trading this but also hold some long shares for the real spike coming down the road. Accoding to StockTA there is support at .28. We will see if that holds and if it doesn't I will be adding a lot more to my position here. glta longs!
dam Ihub lol
yes it is
btw, this is not a nda but a reformulation of one made by GSK so the fda approval will be closer to 6mos rather than 2 yrs imo.
yes it is
btw, this is not a nda but a reformulation of one made by GSK so the fda approval will be closer to 6mos rather than 2 yrs imo.